Company ProfilePremium

Shunten International (Holdings) Limited

Company Profile Analysis

Ticker: 0932.HK

ESOMAR 23 Corporate BadgeISO Certifications Badge
Shunten International (Holdings) Limited - Company showcase

Year Founded & Workforce

2002

236 Employees

Shunten International (Holdings) Limited logo

Shunten International (Holdings) Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Shunten International (Holdings) Limited Overview

Shunten International is a Hong Kong micro-cap that develops, manufactures, markets and distributes health and beauty supplements. It also runs a small and shrinking property investment portfolio. Its anchor franchise is "Royal Medic" (御藥堂), a traditional-Chinese-medicine-inspired supplement brand. The brand is promoted heavily on television and through long-standing celebrity ambassadors, and is sold through a dominant Hong Kong/Macau health-and-beauty retail chain (the single largest customer, about 51% of FY2026 revenue). Sales also come from about 60 in-store "special designated counters", the Hong Kong Brands and Products Expo, the group's own e-commerce site, and cross-border platforms such as Tmall. Gross margins are high (about 76–78%), but heavy rent, commission and advertising costs absorb them. The business is fully exposed to Hong Kong retail sentiment and inbound tourism. A leveraged property portfolio has produced HK$61.7M of cumulative fair-value losses over FY2024–FY2026. Since a September 2025 mandatory offer, Chairman Cheung Siu Fai's concert group has held majority control.


Company's own description

In the FY2026 final results announcement, the company describes itself as an investment holding company. Its group is principally engaged in Hong Kong in developing, manufacturing, selling, marketing and distributing health and beauty supplements and products, and in property investment. The FY2024 announcement had described the business more narrowly as "sale, marketing and distribution". Adding "development and manufacturing" in FY2026 reflects the company's emphasis on in-house formulation and its R&D centre.

Management describes two brand architectures:

Proprietary brands: are developed and managed by the group. The FY2026 list is 御藥堂 (Royal Medic), 中大中藥傳承 (Legend), 溶腩酵素 (MeltyEnz), 淨腸酵素 (CleansingEnz), 格斯圖 (La Gusto), Prof Health, HARUKA, 男鋼75 (Mr.

Private label: 康寶庫 ("Health Proof") is developed specifically for, and owned by, a well-known health-and-beauty retail chain in Hong Kong and Macau.

Business model and revenue model

DimensionCharacterisation
Revenue typeAbout 97.7% product sales (health & beauty supplements), recognised at a point in time on delivery. About 2.3% rental income from investment properties under fixed-rent operating leases (FY2026).
Subscription / licensingNone disclosed. A loyalty scheme ("RM Club") awards points that expire every 31 March.
Principal vs agentAll product revenue is recognised as principal (FY2026 Note 4)
ReturnsSome contracts carry return rights; refund liabilities were HK$1.4M at 31 Mar 2026
New revenue line (FY2026)Service income from using the group's promoter team to market traditional Chinese medicine products for industry peers. It is booked in "other income" and lifted that line to HK$3.1M from HK$0.9M.
Credit terms0–90 days to customers; 0–90 days from suppliers

Value chain position

The group spans formulation and R&D (Royal Medic R&D Centre, Hong Kong Science Park), manufacturing (in-house, plus subcontracting cited as a component of cost of sales), brand marketing, and distribution and retail. Its retail presence runs through counters inside a third-party chain rather than a self-owned store network. Cost of sales covers raw and packaging materials, production staff and subcontracting costs. That cost base is small at HK$48.2M in FY2026, about 24% of revenue. The value capture problem lies downstream: counter rent (HK$34.1M), promoter commissions, advertising and celebrity endorsements, and administrative salaries absorb the gross margin.

Customer types and end-markets

Retail chain distributor (B2B2C): "Customer A" contributed HK$102.6M (51.2% of revenue) in FY2026. It had contributed HK$111.9M (54.6%) in FY2025, HK$137.4M (58.3%) in FY2024 and HK$160.9M (74.5%) in FY2023. The customer is not named in filings. The description (a renowned Hong Kong/Macau health-and-beauty chain that owns the "Health Proof" private label) is consistent with a market-leading pharmacy chain, but that identification is an unconfirmed inference.

Direct consumers (B2C): through special designated counters, which are counters inside the chain's stores staffed by group promoters, with rent calculated on gross counter sales. Also through the HK Brands and Products Expo, the own e-commerce platform, and stores on third-party and cross-border platforms.

End-markets: Hong Kong local consumers, Macau, and mainland Chinese visitors and cross-border online buyers. All product revenue is booked as Hong Kong-domiciled revenue (FY2024 Note 4).

Independent characterisation

Shunten is in practice a single-market, brand-led consumer health franchise that depends on one channel. It trades as a deep-value micro-cap whose balance sheet has been weighed down by property speculation. The supplement business generates positive segment profit, but that profit has collapsed from HK$69.6M (FY2023) to HK$8.9M (FY2026). Over the same period, revenue fell only from HK$215.9M to HK$195.7M. The cost structure is therefore sticky and largely fixed or variable-to-channel. The principal value drivers are Hong Kong tourist and resident retail spending, the terms of the dominant retail partner, and the success of a heavy new-product cadence.

Strategy

Stated strategic themes (FY2026 annual results, paraphrased)

  1. Portfolio enrichment and accelerated R&D: launch innovative products and new brands that broaden functional benefits for health-conscious consumers (e.g. Cordyceps Cs-4, 淨肝健 2.0, the 御方正品 brand).

  2. Celebrity-led marketing: continue the long partnership with Michelle Yim, and add Aimee Chan and 許博文 for 2026 launches across TV, social media and roadshows. The tagline is "為您健康把關" ("guarding your health").

  3. Omni-channel optimisation: add special designated counters at selected locations, and upgrade third-party online stores and the own e-commerce platform.

  4. Strict cost discipline: control raw-material procurement, logistics, advertising and operating expenses to protect margins.

  5. Prudent property management: maintain occupancy and stable rental income; recycle capital when timing is right (Mid-Levels exit).

  6. Capital-structure flexibility: AGM resolutions in September 2026 proposed an increase in authorised share capital and new articles, plus general mandates to issue and buy back shares. The specific purpose was not stated in the materials reviewed. It is an enabling step that could facilitate future equity issuance.

Initiatives in the last 24 months

DateInitiativeTypeDetail / target
Jun 2024Tmall flagship storeChannel / PRC expansionReach mainland consumers
Jun 2024New CRM system and RM Club member appDigitalData-driven marketing and product development
FY2025–FY2026New and upgraded SKUs (強胃健, 參睡紫靈芝, 一錠速眠, 速祛濕 upgrade)ProductRevenue defence
FY2026Online stores on well-known e-commerce platformsChannelDigital customer acquisition
FY2026Promotion services for peers' TCM productsNew revenue lineMonetise promoter team
FY2026Department restructuring; one-off retirement settlementsCost / organisationTargets not quantified
Jul–Oct 2025Mid-Levels residential disposal (HK$28.0M)Capital recyclingDeleveraging and working capital
Apr 2026Cordyceps Cs-4 and 淨肝健 2.0 campaignsProduct / marketingMulti-channel campaign
Jul 2026Authorised share capital increase; new articlesCorporate financeFlexibility

ESG commitments. An ESG report is included in each annual report.

Medium-term financial targets / guidance. None published. The company issues profit warnings and alerts under Listing Rule 13.09 but provides no forward guidance.

Products & Services

Pricing, detailed specifications and SKU counts are not disclosed in the HKEX filings reviewed. Product descriptions below draw only on filing disclosures. Functional descriptions inferred from product names are flagged as such.

Health & Beauty Supplements and Products segment

Brand / productTypeDescription and positioningTarget customerLaunch / latest versionSource
御藥堂 Royal Medic (master brand)ProprietaryFlagship TCM-inspired health supplement brand. Spokespersons Michelle Yim (米雪, long-standing), Michael Miu (苗僑偉, FY2024), Aimee Chan (陳茵媺) and 許博文 "Johnny" (from Apr 2026).Mass-market HK consumers, historically middle-aged and older; management seeks to attract younger buyersBrand predates 2013 IPOFY2024 & FY2026 MD&A
御藥堂強胃健New SKUName suggests a digestive and stomach health supplement (functional description inferred)Adults with digestive concernsLaunched FY2026FY2026 MD&A
御藥堂參睡紫靈芝New SKUGinseng and purple lingzhi blend; name suggests a sleep aid (inferred)Adults with sleep issuesLaunched FY2026FY2026 MD&A
御藥堂速祛濕Upgraded best-sellerName suggests a "dampness-dispelling" TCM supplement (inferred)TCM-oriented consumersUpgraded version FY2026FY2026 MD&A
御藥堂賦活蟲草 Cs-4New SKUCordyceps (Cs-4 strain) supplement; ambassador Aimee ChanEnergy and vitality segmentLaunched after 31 Mar 2026FY2026 MD&A (Outlook)
御藥堂淨肝健 2.0Upgraded SKUName suggests a liver-health supplement (inferred); ambassador 許博文AdultsVersion 2.0 launched after 31 Mar 2026FY2026 MD&A (Outlook)
NMN product (Royal Medic range)New categoryNicotinamide mononucleotide anti-ageing supplement; spokesperson Hins Cheung (張敬軒)Ages 20–60 (management's stated fan-base reach)Launched FY2024FY2024 MD&A
中大中藥傳承 LegendProprietaryTCM heritage-positioned line (detail not disclosed)——FY2024/26 MD&A
溶腩酵素 MeltyEnzProprietaryEnzyme product; name suggests body-shaping and weight management (inferred)Beauty and slimming segment—FY2024/26 MD&A
淨腸酵素 CleansingEnzProprietaryEnzyme product; name suggests digestive cleansing (inferred)Beauty and wellness—FY2024/26 MD&A
格斯圖 La GustoProprietaryDetail not disclosed——FY2024/26 MD&A
HARUKAProprietaryJapanese-styled brand name; detail not disclosed——FY2024/26 MD&A
男鋼75 Mr. 75ProprietaryName suggests a men's health supplement (inferred)Adult men—FY2024/26 MD&A
Prof HealthProprietaryAdded to brand list by FY2026; detail not disclosed——FY2026 MD&A
御方正品 (incl. 一錠速眠)Proprietary (new brand)New brand. 一錠速眠 ("one-tablet fast sleep") launched FY2026; sleep positioning inferred from the name.Sleep segmentFY2026FY2026 MD&A
康寶庫 Health ProofPrivate labelDeveloped for, and owned by, a renowned HK/Macau health-and-beauty retail chainThe chain's shoppers—FY2024/26 MD&A

Services and channels within the segment

OfferingDescriptionYear
Special designated countersGroup-staffed counters inside a chain distributor's stores, including at HK International Airport and cross-border points such as Lok Ma Chau MTR (reopened FY2024). 61 counters at 31 Mar 2024 (55 at 31 Mar 2023); FY2025 and FY2026 counts not disclosed in the announcements; expansion to "selected locations" planned.Ongoing
Own e-commerce platformDirect-to-consumer web store; marketing stepped up in FY2026Ongoing
Third-party e-commerce storesOnline stores opened on "well-known e-commerce platforms" (platforms not named)FY2026
Tmall flagship storeCross-border store for mainland consumersJun 2024
RM Club loyalty app and CRMPoints balance and redemption, customer data analyticsJun 2024
HK Brands and Products ExpoAnnual trade-fair sales channelRecurring
Promotion services for industry peersGroup promoter team markets peers' TCM products; booked as other incomeFY2026
Earlier: OEM, general administrative and management services; licence and trademark holdingListed in third-party business descriptionsHistoric / ongoing (n.d.)

Property Investment segment

AssetLocationUseStatus
5-storey tenement building, 127 Kweilin StreetSham Shui Po, KowloonCommercial and residential lettingsHeld; acquired via company acquisition 13 Mar 2023
Industrial propertyKwai Chung, NTIndustrial lettingHeld; reclassified from owner-occupied in FY2024
Residential propertyMid-Levels, HK IslandResidential lettingSold via subsidiary disposal for HK$28.0M, completed 16 Oct 2025

The investment property carrying value was HK$132.4M at 31 Mar 2026, down from HK$176.7M (FY2025) and HK$207.1M (FY2024). All of it is pledged for bank borrowings.

Financial Narrative

Basis. FY2023–FY2026 are taken from audited figures in the FY2024 and FY2026 final results announcements. FY2022 uses the originally reported continuing-operations figures from the FY2021/22 annual report (revenue HK$163.0M, re-presented to HK$155.6M in FY2023). Its operating income, EBITDA and pre-tax lines come from a TipRanks aggregation and are flagged as secondary-source. FY2021 revenue was HK$223.1M and the loss attributable HK$127.4M (FY2021/22 annual report).

Income statement

Notes:

  • D&A is PP&E depreciation plus right-of-use depreciation plus intangible amortisation, taken from segment notes.

  • EBITDA is analyst-computed as operating income plus D&A. It reconciles to the aggregator figures for FY2023–FY2025.

  • No dividend has been declared or paid in any year FY2023–FY2026.

Margins and growth

Revenue CAGR. FY2022–FY2026 is +5.3% p.a. on the as-reported FY2022 base, or +6.5% on the re-presented HK$155.6M base. FY2023–FY2026 is −2.5% p.a. FY2021–FY2026 is −2.1% p.a. (all analyst-computed).

Commentary. The income statement shows a post-COVID rebound followed by a reversal.

FY2022→FY2023: revenue rose 32.6%, helped by reopening and a HK$11.9M fair-value gain.

FY2024: the revenue peak was HK$235.6M, driven by border reopening, consumption vouchers, reopened airport and border counters, and advertising. Profit nonetheless almost vanished. Admin expenses rose 21.7%, mainly sales-linked counter rent, which nearly doubled from HK$16.9M to HK$32.7M. S&D rose 15.0% on promoter commissions, and a HK$15.0M fair-value loss swung the property line.

FY2025: revenue fell 13.0%. Management attributes this to weak local consumption, outbound spending by residents, and visitors shifting from shopping to experiential travel. The operating cost base did not flex: S&D was HK$53.1M and admin HK$102.0M. The adjusted result moved to a loss of HK$5.8M.

FY2026: the headline loss narrowed to HK$26.6M because the fair-value loss halved to HK$16.3M and finance costs fell 31.9%. The adjusted loss, however, widened to HK$10.3M. Staff costs rose to HK$80.2M with restructuring and retirement settlements, counter rent rose to HK$34.1M, and higher input costs trimmed gross margin by about 1.1 points to 75.9%.

Balance sheet

Notes:

  • FY2022 borrowings include bank and other borrowings and overdrafts.

Short/long split: all bank borrowings are classified as current because of repayment-on-demand clauses. At 31 Mar 2026 they comprised HK$84.0M current and nil non-current, all secured on leasehold land and buildings (HK$6.9M) and investment properties (HK$132.4M). Unused facilities at 31 Mar 2026 were HK$10M of banking facilities plus a HK$15M shareholder loan facility (FY2025: HK$10M and HK$18M; FY2024: HK$40M banking).

Balance sheet commentary. The FY2024 jump in investment properties to HK$207.1M was mostly a reclassification of owner-occupied premises, which is why PP&E fell from HK$68.4M to HK$12.7M. It also included a HK$27.8M OCI revaluation surplus, so it was not new investment. Since then, HK$45.7M of fair-value losses and the HK$28.0M Mid-Levels disposal have cut the portfolio by 36%. The disposal proceeds mainly retired bank debt, which fell by HK$34.9M in FY2026. Equity has fallen 37% from the FY2024 peak. The going-concern note in FY2026 records net current liabilities of HK$50.2M against cash of HK$7.4M. It relies on operating cash flows, covenant compliance, the pledged properties, and the shareholder's undrawn HK$15M facility.

Cash flow

Capex proxies come from segment "other information" notes. There were no buybacks in FY2023–FY2026 ("neither the Company nor any subsidiary purchased, redeemed or sold listed securities"). Indirect evidence: net debt excluding leases fell HK$31.7M in FY2026. Of that, HK$28.0M came from the disposal, which implies only modest internally generated cash after interest and leases.

Ratios (analyst-computed unless stated)

Ratio commentary.

  • Liquidity is structurally thin: the current ratio has been about 0.5–0.6x for four years.

  • Leverage measured against cash earnings has deteriorated sharply. Excluding the property fair-value line, FY2026 EBITDA of about HK$6.5M did not cover finance costs plus lease payments by a comfortable margin.

  • The long cash conversion cycle (about 190–220 days) is driven by inventory. It is typical of a supplement maker carrying raw materials and finished goods, but it ties up roughly HK$22–26M.

  • Receivable days are healthy because the dominant customer pays within 60 days. Overdue balances did rise to HK$8.1M at 31 Mar 2026 from HK$3.4M.

Half-year trend

H1 FY2026 adjusted net loss was HK$6.3M, against an adjusted profit of HK$2.7M in H1 FY2025. The fair-value loss was HK$6.3M (H1 FY2025: HK$7.0M). Gearing was 101.3% at 30 Sep 2025. Sources: interim announcements (Nov 2023, Nov 2025) and Nov 2024 profit warning coverage.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

SegmentFY2023FY2024FY2025FY2026

Health & beauty supplements revenue (HKD Mn)

215.9230.6199.9195.7

Property investment revenue (HKD Mn)

0.25.05.14.6

Total revenue (HKD Mn)

216.1235.6205.0200.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025FY2026

H&B segment result (HKD Mn)

69.652.120.18.9

Property segment result incl. FV change (HKD Mn)

11.8-15.4-29.6-14.8

Property segment result excl. FV change (HKD Mn, analyst-computed)

-0.1-0.40.81.5

H&B segment margin (%)

32.222.610.14.5

H&B revenue YoY growth (%)

—6.8-13.3-2.1

Property revenue YoY growth (%)

—2,318.42.5-10.2

H&B share of group revenue (%)

99.997.997.597.7

Property share of group revenue (%)

0.12.12.52.3

Unallocated corporate expenses (HKD Mn)

32.929.621.520.7

Segment Assets & Liabilities

MetricFY2023FY2024FY2025FY2026

H&B segment assets (HKD Mn)

157.0110.594.780.1

Property segment assets (HKD Mn)

136.9208.4178.0134.1

Unallocated assets (HKD Mn)

45.525.416.213.9

H&B segment liabilities (HKD Mn)

23.716.549.629.7

Property segment liabilities (HKD Mn)

81.576.246.944.1

Unallocated liabilities (HKD Mn)

90.880.057.045.3

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

163.0216.1235.6205.0200.3

Cost of sales (HKD Mn)

50.449.851.447.148.2

Gross profit (HKD Mn)

112.5166.3184.2158.0152.1

Other income, gains or losses (HKD Mn)

—3.91.60.93.1

Selling & distribution expenses (HKD Mn)

—47.454.553.153.4

Administrative expenses (HKD Mn)

—85.3103.8102.0106.4

Fair value change of investment properties (HKD Mn)

—11.9-15.0-30.4-16.3

Operating income before finance costs (HKD Mn)

-28.848.712.4-26.4-21.2

Depreciation & amortisation (HKD Mn)

—6.59.111.811.5

EBITDA reported basis (HKD Mn)

-18.555.221.5-14.6-9.8

EBITDA excl. investment property FV change (HKD Mn)

—43.336.515.86.5

Finance costs (HKD Mn)

—5.07.86.94.7

Pre-tax income continuing (HKD Mn)

-41.643.84.6-33.4-25.9

Taxation (HKD Mn)

—2.64.12.90.7

Net income attributable to owners (HKD Mn)

-43.941.00.6-36.2-26.6

Adjusted net profit/(loss) company-defined (HKD Mn)

—24.815.6-5.8-10.3

Basic & diluted EPS (HK cents)

—1.320.02-1.17-0.85

Dividend per share (HK cents)

—0000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

69.076.978.277.075.9

Operating margin (%)

-17.622.55.2-12.9-10.6

EBITDA margin reported (%)

-11.325.69.1-7.1-4.9

EBITDA margin excl. FV (%)

—20.015.57.73.3

Net margin (%)

-26.919.00.2-17.7-13.3

Revenue YoY growth (%)

-27.032.69.0-13.0-2.3

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (HKD Mn)

—339.4344.3288.9228.0

Investment properties (HKD Mn)

—136.9207.1176.7132.4

Property plant & equipment (HKD Mn)

—68.412.711.09.3

Intangible assets (HKD Mn)

—7.416.319.314.9

Goodwill (HKD Mn)

—0000

Inventories (HKD Mn)

—23.825.924.922.2

Trade receivables net (HKD Mn)

—40.027.724.024.6

Cash & cash equivalents (HKD Mn)

35.313.112.75.57.4

Bank & other borrowings (HKD Mn)

119.079.7111.0119.084.0

Amount due to a shareholder (HKD Mn)

—79.925.905.0

Lease liabilities total (HKD Mn)

—6.811.210.04.8

Total borrowings incl. shareholder loan (HKD Mn)

—159.6136.9119.089.0

Net debt excl. leases (HKD Mn)

83.7146.5124.2113.481.7

Total liabilities (HKD Mn)

—196.0172.7153.6119.1

Equity attributable to owners (HKD Mn)

—146.0172.9136.6110.2

Total equity (HKD Mn)

—143.4171.6135.3108.9

Net working capital (HKD Mn)

-65.8-94.9-79.5-75.4-50.2

Cash Flow

MetricFY2023FY2024FY2025FY2026

Capex: additions to PP&E (HKD Mn)

1.95.00.40.4

Additions to intangible assets (HKD Mn)

5.510.06.80

Dividends paid (HKD Mn)

0000

Share buybacks (HKD Mn)

0000

Disposal proceeds (HKD Mn)

———28.0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

ROE on average owners' equity (%)

28.10.4-23.4-21.5

ROA on year-end total assets (%)

12.10.2-12.5-11.7

ROIC: EBIT×(1−16.5%) / (equity + net debt) (%)

14.03.5-8.9-9.3

Current ratio (x)

0.510.520.480.57

Gearing: total borrowings / equity, company-reported (%)

111.379.887.981.8

Net debt / EBITDA excl. FV (x)

3.43.47.212.6

Interest coverage EBIT / finance costs (x)

9.81.6-3.8-4.6

Interest coverage excl. FV (x)

7.43.50.6-1.1

Asset turnover on average assets (x)

—0.690.650.77

Days inventory outstanding (days)

174.5183.9192.9168.5

Days sales outstanding (days)

67.642.842.744.9

Days payables outstanding (days)

22.316.729.920.5

Cash conversion cycle (days)

219.8210.0205.7192.9

Income Statement

MetricH1 FY2023H1 FY2024H1 FY2025H1 FY2026

Revenue (HKD Mn)

112.3128.0103.0102.1

H&B revenue (HKD Mn)

——100.299.4

Gross profit (HKD Mn)

86.198.279.777.3

Profit/(loss) attributable (HKD Mn)

18.710.8-4.3-12.6

Revenue by Region and Region Margins & Growth (%)

RegionFY2023FY2024FY2025FY2026

Hong Kong revenue as reported (HKD Mn)

216.1235.6205.0200.3

Hong Kong YoY growth (%)

—9.0-13.0-2.3

Segment × Geography Details

Segment × geographyFY2026 (HKD Mn)Basis

H&B, Hong Kong (incl. any Macau/PRC flows)

195.7

All booked in HK

Property, Hong Kong

4.6

All properties in HK

Valuation Snapshot

MetricValueSource / basis

Share price, early–mid Jul 2026

HK$0.027–0.028

etnet quotes (3, 16, 17 Jul 2026)

Share price, 27 Dec 2024

HK$0.032

Moomoo snapshot (market cap HK$99.45M)

Implied MGO acceptance value

≈HK$0.024 per share

HK$1.3M ÷ 53.888M shares (analyst-derived)

Market cap at HK$0.028

≈HK$87.0M

3,107.893M shares

Enterprise value

≈HK$173M

Market cap + borrowings HK$84.0M + shareholder loan HK$5.0M + leases HK$4.8M − cash HK$7.4M (31 Mar 2026)

Multiple (at HK$0.028, FY2026 basis)

Value

—

P/E (x)

n.m. (loss-making)

—

EV/EBITDA reported (x)

n.m. (negative)

—

EV/EBITDA excl. FV (x)

≈26.6

—

EV/Sales (x)

≈0.86

—

P/B on owners' equity HK$110.2M (x)

≈0.79

—

Capital Markets

ItemDetail

Analyst consensus

No sell-side coverage identified

Dividend history

Nil for FY2023, FY2024, FY2025 and FY2026; no interim dividend H1 FY2026

Dividend policy

Capital management statement: balance via dividends, issues and debt "as appropriate". No formal payout policy identified.

Buybacks

General repurchase mandate sought at AGMs; no repurchases FY2023–FY2026

Credit ratings

None (Moody's / S&P / Fitch: not rated)

Debt maturity profile

All bank borrowings (HK$84.0M) classified current due to repayment-on-demand clauses

Unused facilities (31 Mar 2026)

HK$10M bank; HK$15M shareholder loan facility

Pledged assets

Investment properties HK$132.4M; leasehold land and buildings HK$6.9M

Liquidity

Average daily volume about 1.8–8.2M shares around the 2025 offer (TipRanks snapshots); very low value traded

Analyst Conclusions

Management guidance

No quantitative guidance is given. The FY2026 outlook expects a still-challenging HK retail environment because of geopolitical tensions, uncertainty, changing consumption patterns and competition. Management's priorities are faster R&D and new brands, celebrity-led campaigns from April 2026, more counters, upgraded online stores, strict cost control, and a cautious approach to property with an occupancy focus. Consensus: none available.

Bull case

  1. Cost reset plus product cycle: FY2026 absorbed one-off restructuring and retirement settlements and launch-heavy marketing. If these do not recur, gross margin holds at about 76%, and the Cs-4 and 淨肝健 2.0 launches stabilise H&B revenue at about HK$195–200M, then segment profit could recover toward the FY2025 level of HK$20.1M.

  2. Deleveraging and asset backing: gearing fell from 111.3% (FY2023) to 81.8% (FY2026). The stock trades at about 0.79x book, and HK$132.4M of property remains available to recycle.

  3. Control consolidation: the controller now holds about 50.5% and has added an investment-management executive director. This could lead to strategic actions such as restructuring, new capital or business injection, or a privatisation attempt.

Bear case

  1. Structural margin erosion: adjusted results moved from +HK$24.8M (FY2023) to −HK$10.3M (FY2026). Counter rent (HK$34.1M) and staff costs (HK$80.2M) both rose in a year when revenue fell.

  2. Liquidity fragility: HK$7.4M of cash, HK$84.0M of on-demand debt and HK$50.2M of net current liabilities leave the company dependent on lender forbearance and shareholder support.

  3. Dilution and concentration: the July 2026 authorised-capital increase opens room for share issuance near HK$0.03 per share. Meanwhile, half of revenue depends on one retailer's goodwill.

Catalysts and monitorables (next 12 months)

Late Nov 2026: H1 FY2027 interim results. Watch the early sales impact of the Cs-4 and 淨肝健 2.0 launches, S&D intensity, and any profit warning issued about two weeks earlier.

Ongoing: any share issuance, placing or rights issue using the enlarged authorised capital.

Ongoing: property revaluations at Sept 2026 and Mar 2027, and any further asset disposals.

Ongoing: bank facility renewals and the use of the shareholder loan facility.

Ongoing: Customer A revenue share, counter count and counter rent trajectory.

Ongoing: board and management changes after the change of control, and any strategic announcements by Leading Virtue.

June 2027: FY2027 final results.

Analyst verdict

Shunten is a branded consumer-health franchise held back by its own cost structure and a speculative property detour. The core facts are stark. Gross margin has stayed in a tight 75.9–78.2% band for four years, so the product economics are intact. Yet H&B segment profit has fallen from HK$69.6M to HK$8.9M. The leak sits below gross profit, in sales-linked counter rent, promoter commissions, celebrity advertising and a HK$106M administrative base that does not flex when Hong Kong retail softens. Meanwhile, the property book has cost shareholders HK$61.7M in fair-value losses in three years and consumed balance-sheet capacity. The HK$28M Mid-Levels sale was the right move, but it was reactive.

The balance sheet is the binding constraint. Cash of HK$7.4M against HK$84.0M of on-demand bank debt means the company runs on lender confidence and a HK$15M shareholder line. That makes the September 2025 change of control and the July 2026 authorised-capital increase the most important developments for minority holders. They point to either fresh capital or a broader corporate action. Investors should treat the stock as an event-driven special situation rather than an operating compounder.

On valuation, the shares trade at roughly 0.8x book and 0.9x sales. That is cheap only if book value, which is largely Hong Kong secondary property, holds and the supplement business returns to positive adjusted earnings. Neither condition has yet been met. For the core business to turn, revenue needs to stabilise around HK$200M while counter rent and staffing are held flat. On FY2026 numbers, that would add roughly HK$10M of operating leverage. Until the interim results show evidence of this, the risks remain concentrated: one dominant customer, one market, and on-demand debt. The overall assessment is speculative and neutral-to-negative, with upside tied mainly to corporate action rather than operations. Key watchpoints are the November 2026 interims and any capital-raising announcement.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / notesCommittees

CHEUNG Siu Fai (張少輝)

Chairman and Executive Director

Signs all announcements since at least FY2023. Concert party with offeror Leading Virtue. Born 1970 (market data profile).

—
—

Executive Director

Appointed April 2026. A responsible officer of an asset manager (黑馬資本).

—

SO Tsz Kwan (蘇芷君)

Non-Executive Director

Chaired the 3 Sep 2025 AGM in the Chairman's absence

—

LEUNG Winson Kwan Yau (梁鈞滺)

Independent NED

Audit Committee Chairman

Audit (Chair)

DONG Jian Mei (董建美)

Independent NED

On board since at least FY2024

Audit

—

Independent NED

—

Audit

Executive Leadership Team

NameTitleYear of birth

Yeung Wai Lok

Chief Executive Officer

1969

Wong Chak Man

Chief Financial Officer

1982

Cheng Tze Kit

Group Chief Investment Officer

1956

Yan Tat Ming

COO, Health, Beauty Supplements & Products

1964

Lee Chi Hang

Chief Legal Adviser, H&B segments

1964

Tsang Chi Wai

Chief Compliance Officer

1964

Chong Siu Yu

Sales Director

1974

Wong Suet Yin

Marketing Director

1981

Yuen Yee Han

Administration Controller

1961

Chan Yuk Chi

Company Secretary

—

Board & Management Changes

DateChangeContext

31 Aug 2022

INED Leung Man Loon departs

Board refresh

Between Jun 2024 and Nov 2025

INED Liu Ying Shun replaced by 林植信

—

3 Sep 2025

Chairman absent from AGM; NED So Tsz Kwan presides

CG Code deviation F.1.3

Apr 2026

周華鴻 appointed Executive Director

First new executive director after the change of control

Major Shareholders

HolderShares% of issuedSource

Leading Virtue Holdings Ltd + concert parties (incl. Cheung Siu Fai)

1,554,534,03350.02%

Joint announcement, 20 Oct 2025 (includes 38.0M acceptances)

Same group after final close (analyst-derived)

≈1,570,422,033

≈50.53%

Adds the further 15.888M acceptances to the 4 Nov 2025 close of 53.888M total

Public float

≈1,537M

≈49.5%

Derived

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning vs Shunten

Eu Yan Sang (private; delisted from SGX)

TCM supplements and retail

Much larger heritage TCM brand with its own store network

Wai Yuen Tong Medicine (HKEX: 0897)

TCM products and supplements

Listed HK TCM peer with own retail

PuraPharm (HKEX: 1498, "Nong's")

Concentrated Chinese medicine granules, supplements

Clinical/TCM orientation; larger

Vita Green (private)

HK health supplements (lingzhi, cordyceps)

Direct overlap in lingzhi and cordyceps; strong own counters

Hin Sang Group (HKEX: 6893)

Health and beauty products, HK/PRC

Listed micro-cap peer

H&H International / Swisse (HKEX: 1112)

Adult nutrition and supplements

Global brand scale; cross-border e-commerce leader

By-health (SZSE: 300146)

Vitamins and supplements, PRC

Mainland scale player relevant to cross-border ambitions

Blackmores (Kirin)

Supplements in HK pharmacy chains

International brand competing for shelf space

Pharmacy-chain private labels

OTC and supplements

Shelf competition; Shunten also supplies one ("Health Proof")

Direct sellers (e.g. Herbalife, Amway Nutrilite, Infinitus)

Supplements

Different channel; overlapping consumers

Competitor Detail

MetricShunten FY2026

Revenue (HKD Mn)

200.3

Revenue growth (%)

-2.3

Gross margin (%)

75.9

Net margin (%)

-13.3

Company Snapshot

$25.7M

Revenue

236

Employees

2002

Founded

Kwai Chung, Australia

Headquarters

SWOT Analysis

Strengths

  • High gross margin: 75.9% in FY2026 and 78.2% in FY2024, showing pricing power typical of branded supplements.
  • Established flagship brand: Royal Medic (御藥堂) has existed since before the 2013 GEM listing (the IPO-era company name was 御藥堂集團控股) and is backed by multi-celebrity campaigns.
  • Channel embeddedness: 61 special designated counters at 31 Mar 2024 (from 55) inside a leading chain, including airport and border locations.
  • Product cadence: at least three new and one upgraded SKU in FY2026, plus two more after year-end. A new brand (御方正品) was created.
  • Clean receivables: receivables are 0–90-day terms with 67% current at 31 Mar 2026, and credit losses are small (HK$0.4M FY2026 impairment).
  • Controlling-shareholder support: an undrawn HK$15M shareholder loan facility (FY2026), and the concert party lifted its stake above 50% in Oct 2025.

Weaknesses

  • Operating deleverage: H&B segment profit fell from HK$69.6M (FY2023) to HK$8.9M (FY2026) while revenue fell only 9%.
  • Customer concentration: Customer A was 51.2% of revenue (FY2026) and 74.5% (FY2023).
  • Liquidity: current ratio 0.57x, net current liabilities HK$50.2M, cash HK$7.4M (31 Mar 2026). All bank debt is repayable on demand.
  • Heavy fixed costs: admin HK$106.4M plus S&D HK$53.4M, together 80% of revenue in FY2026.
  • Capital misallocation into property: HK$61.7M cumulative FV losses in FY2024–FY2026 against a peak portfolio of HK$207.1M.
  • Governance gaps: the Chairman missed the 2025 AGM and held no INED-only meeting (CG Code deviations C.2.7 and F.1.3). No dividends have been paid in four years.

Opportunities

  • Mainland reach: cross-border e-commerce via Tmall (since Jun 2024) and other platforms.
  • Ageing and wellness categories: NMN, cordyceps, sleep and liver lines align with demographic demand.
  • Ancillary income: monetising the promoter team for peers' TCM products, a new FY2026 income line that lifted other income to HK$3.1M.
  • Tourism normalisation: further normalisation in HK could restore airport and border counter productivity (FY2024 precedent: +6.8% H&B revenue).
  • Further property recycling: HK$132.4M of remaining property could cut debt further, as in the Mid-Levels precedent.
  • New controlling shareholder: this could bring a strategic reset; an asset-management executive joined the board in April 2026.

Threats

  • Regulation: changes for TCM-ingredient foods and supplements, flagged by the company as a principal risk.
  • Structural spending leakage: residents spending in Shenzhen and changed visitor behaviour (FY2025–FY2026 MD&A).
  • Partner terms: the dominant retailer could alter terms, raise counter rent (already HK$34.1M) or favour private labels.
  • Property: further declines in HK commercial and industrial values could trigger covenant pressure on pledged-property loans.
  • Interest rates: finance costs were HK$4.7M in FY2026 on floating-rate borrowings.
  • Dilution: the authorised capital increase proposed in July 2026 raises the possibility of future equity issuance at about HK$0.03 per share.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Jun 2025Profit warning: FY2025 loss of HK$33–39M vs FY2024 profit of about HK$0.6M, citing weak HK/Macau consumption, visitor pattern shifts and property FV declineSwing to loss
Jun 2025Board meeting notice for 26 Jun 2025 results and dividend considerationRoutine
26 Jun 2025FY2025 results: revenue HK$205.0M (−13.0%); loss HK$36.2M; adjusted loss HK$5.8M; no dividendConfirms deterioration
14 Jul 2025Provisional SPA to sell Mid-Levels property subsidiary for HK$28.0MDeleveraging
25 Jul 2025Annual Report 2024/25 publishedFiling
3 Sep 2025AGM; Chairman absent, NED So Tsz Kwan presidesGovernance deviation
Sep 2025Leading Virtue and Cheung Siu Fai agree to acquire about 24.65%, triggering a mandatory conditional cash offer (Prime Securities)Change of control
Late Sep 2025Composite document dispatch deadline extended to 14 Oct 2025 to finalise financial and valuation contentOffer timetable
Oct 2025Composite document dispatchedOffer opens
16 Oct 2025Formal SPA signed and Mid-Levels disposal completedHK$28.0M cash received
20 Oct 2025Offer unconditional; concert group at 50.02%Majority control secured
4 Nov 2025Offer closes; nine acceptances totalling 53.888M shares (1.73%); about HK$1.3M considerationLow take-up
14 Nov 2025Profit warning: H1 FY2026 loss of HK$8–13M, citing advertising for new products, promoter commissions, input and packaging costs, and counter rentLoss widening
26 Nov 2025Interim results: revenue HK$102.1M; loss HK$12.6M; adjusted loss HK$6.3M; gearing 101.3%; no interim dividendConfirms trend
Dec 2025 – May 2026Monthly returns of equity issuer filed; no share issuance indicated in sourcesRoutine
Apr 2026周華鴻 appointed Executive DirectorBoard strengthening post-offer
Apr 2026Launch campaigns for 御藥堂賦活蟲草 Cs-4 (Aimee Chan) and 淨肝健 2.0 (許博文) across TV, social media and roadshowsMarketing push
15 Jun 2026Board meeting notice; positive profit alert (loss reduced)Narrowing loss
26 Jun 2026FY2026 results: revenue HK$200.3M (−2.3%); loss HK$26.6M; adjusted loss HK$10.3M; no dividend; AGM set for 2 Sep 2026Mixed
2 Jul 2026Monthly return for June 2026Routine
23 Jul 2026Proposed increase in authorised share capital; adoption of new M&APotential future equity capacity
24 Jul 2026Annual Report 2025/26, circular and AGM notice publishedFiling
2 Sep 2026Governance

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 163 Mn in FY2022 to HKD 200.3 Mn in FY2026.
Shunten International (Holdings) Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue163216.1235.6205200.3
Cost of sales50.449.851.447.148.2
Gross profit112.5166.3184.2158152.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. HKEX: Final Results Announcement FY ended 31 Mar 2026 (26 Jun 2026; via cninfo mirror static.cninfo.com.cn/finalpage/2026-06-26/1225391963.PDF)
  2. HKEX: Final Results Announcement FY ended 31 Mar 2025 (26 Jun 2025; hkexnews.hk/listedco/listconews/sehk/2025/0626/2025062601756.pdf and Chinese version …01757_c.pdf)
  3. HKEX: Final Results Announcement FY ended 31 Mar 2024 (27 Jun 2024; …/2024/0627/2024062701316.pdf)
  4. HKEX: Final Results Announcement FY2023 (27 Jun 2023) · FY2020 (29 Jun 2020)
  5. HKEX: Annual Reports 2021/22 (…/2022/0722/2022072200487.pdf), 2022/23 (…/2023/0721/2023072100045.pdf), 2024/25 contents (…/2025/0725/2025072500062_c.pdf)
  6. HKEX: Interim Results Announcement six months ended 30 Sep 2025 (…/2025/1126/2025112601160.pdf) · Interim results six months ended 30 Sep 2023
  7. HKEX: Profit warnings 16 Jun 2025 (…/2025/0616/2025061600746_c.pdf), 14 Nov 2025 (…/2025/1114/2025111401299_c.pdf), Jun 2023
  8. HKEX GEM: RM Group Holdings Form F information sheets (2013–2015); announcements 19 Sep 2014 (UShopin) and 23 Jun 2015 (Royal Richly) · Annual Report 2013/14
  9. Offer coverage: Tiger Brokers Bulletin Express (20 Oct 2025, 26 Nov 2025), TTM (4 Nov 2025), TipRanks and Techleap feeds (Sep–Nov 2025)
  10. Market data (secondary): etnet.com.hk quotes and announcement list (Jul 2026) · Moomoo company profile · Yahoo Finance profile · Finnomena profile · TipRanks income statement; stockstar.com notice (24 Jul 2026) · MarketScreener insider records

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.